# EARLY PHASE CLINICAL RESEARCH SUPPORT (Core 14)

> **NIH NIH P30** · UNIVERSITY OF PENNSYLVANIA · 2020 · $536,798

## Abstract

Project Summary 
The Abramson Cancer Center (ACC) has a long and successful track record of conducting innovative pilot and 
Phase I clinical trials, including studies targeting specific molecular pathways relevant to cancer, angiogenesis 
inhibition, cell-based therapy, and stem cell transplantation. Early Phase Clinical Research Support (EPCRS) 
has been particularly helpful in supporting the conduct of high priority, innovative, pilot and/or Phase I clinical 
trials. The pilot and Phase I trials that receive funding via this mechanism are of the highest priority for the ACC 
as they often lay the groundwork for future efficacy studies. Trials supported by EPCRS include both traditional 
“investigator-initiated” studies of short duration (e.g., 1-2 years) and studies that result from collaborations with 
industry in which the ACC investigator is the primary contributor to the design and conduct of the trial and often 
has conducted the preclinical research that provided the rationale for the study. 
The primary focus of EPCRS during the project period has been to enable the conduct of innovative early 
phase trials. Funds have been used to support oncology research nurses and data managers for qualified, 
carefully selected trials. Studies supported by EPCRS, while highly meritorious, are often unfunded or under- 
funded, and thus unable to cover research nursing and/or data management costs adequately without such 
support. In addition, EPCRS funded studies are generally complex, and usually include novel biological 
correlative studies requiring expert study coordination. Consistent with this complexity, the EPCRS-supported 
research nurses and data managers are among our most highly trained staff. EPCRS enables this core group 
of experienced professionals to support ACC investigators in conducting ground-breaking translational 
research studies in a manner that responds to the needs of the investigators and matches the technical 
demands of the individual studies.

## Key facts

- **NIH application ID:** 9836825
- **Project number:** 5P30CA016520-44
- **Recipient organization:** UNIVERSITY OF PENNSYLVANIA
- **Principal Investigator:** Roger B. Cohen
- **Activity code:** P30 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2020
- **Award amount:** $536,798
- **Award type:** 5
- **Project period:** — → —

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/9836825

## Citation

> US National Institutes of Health, RePORTER application 9836825, EARLY PHASE CLINICAL RESEARCH SUPPORT (Core 14) (5P30CA016520-44). Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/grant/nih/9836825. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*